Frederick Health will soon implement "the world's smallest heart pump" into its procedures, which is expected to reduce risks and patient transfers. The Impella, a temporary microaxial intravascular ...

Share on Pinterest Reports of people developing scurvy while taking GLP-1 medications are on the rise. Milles Team/Shutterstock Reports of GLP-1 users developing scurvy have increased in recent months ...

ARTIFICIAL INTELLIGENCE IS PRETTY MUCH EVERYWHERE RIGHT NOW. IT’S NOT JUST CHATGPT. WE’RE VIDEOS AND MISINFORMATION. WHAT? THE TECHNOLOGY COULD SAVE YOUR LIFE. WESH 2’S MEAGHAN TAKES US TO LAKE WEIR ...

At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living ...

BEIJING, Feb 14 (Reuters) - China will implement zero‑tariff treatment for imports from the 53 African countries with which it has diplomatic relations, starting May 1, 2026, state media reported on ...

Vice President JD Vance announced a new push on Wednesday to create price stability in the market for critical rare earth minerals and said he wants to use a familiar Trump-world tool to accomplish it ...

Elon Musk's rocket maker SpaceX has acquired artificial intelligence startup xAI in a deal that will value the company at $1.25 trillion, CNBC has confirmed. The transaction comes ahead of a potential ...

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027. The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for ...

The impact of GLP-1 medications on weight loss is undeniable, but emerging research suggests the results may only be temporary. A growing body of evidence shows that when patients stop taking GLP-1 ...

A sizable percentage of people using Novo (NVO) and Lilly’s (LLY) GLP-1 drugs may be able to sustain their weight loss effects even months after discontinuing the popular obesity drugs, Reuters ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing appetites and nutrition needs. As GLP-1 medications normalize smaller ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...